Photo from wikipedia
One immunotherapeutic agent for patients with advanced non‐small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)‐based assay that predicts response by quantifying programmed death‐ligand 1 (PD‐L1) expression. The current… Click to show full abstract
One immunotherapeutic agent for patients with advanced non‐small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)‐based assay that predicts response by quantifying programmed death‐ligand 1 (PD‐L1) expression. The current study assessed the feasibility of quantifying PD‐L1 expression using cytologic non‐small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens.
Keywords:
lung carcinoma;
cell lung;
cytology;
non small;
small cell
Journal Title: Cancer Cytopathology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Cytopathology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!